GPRC5B

GPRC5B Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag & Flag Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
GPB-H52D7	Human	HEK293	Human GPRC5B Protein, Flag,His Tag (Detergent)				In den Warenkorb legen

Gesamtmenge1

GPRC5B Molekülhintergrund

This gene encodes a member of the type 3 G protein-coupled receptor family. Members of this superfamily are characterized by a signature 7-transmembrane domain motif. The encoded protein may modulate insulin secretion and increased protein expression is associated with type 2 diabetes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2015]

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Atacicept	TACI-Ig	Phase 3 Clinical	Zymogenetics Inc	Glomerulonephritis, IGA; Kidney Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Urinary Bladder Diseases; Lupus Erythematosus, Systemic	Details
Zigakibart	BION-1301	Phase 3 Clinical	Aduro Biotech Inc	Glomerulonephritis, IGA; Proteinuria; Multiple Myeloma	Details
Povetacicept	ALPN-303; ALPN 30x	Phase 3 Clinical		Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis	Details
Sibeprenlimab	VIS-649	Phase 3 Clinical	Visterra Inc	Glomerulonephritis, IGA; Glomerulonephritis	Details
IM-21	IM21; IM-21	Phase 1 Clinical	Beijing Yimiao Medical Technology Co Ltd	Multiple Myeloma	Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)		Phase 1 Clinical	Eugia Pharma Specialities Ltd, Actavis Inc	Multiple Myeloma	Details
anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital）		Phase 1 Clinical	Massachusetts General Hospital	Multiple Myeloma	Details
AUR-200	AUR-200; AUR200	Phase 1 Clinical	Thunderbolt Pharma Inc	Autoimmune Diseases	Details
RO-7297089	RO-7297089; AFM-26; RG-6296	Phase 1 Clinical	Genentech Inc	Multiple Myeloma	Details
APRIL CAR-T Cell therapy (Yake Biotechnology)		Phase 1 Clinical	Shanghai YaKe Biotechnology Co Ltd	Multiple Myeloma	Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)		Clinical	Huazhong University Of Science And Technology	Multiple Myeloma	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Telitacicept	RCT-18; RC-18; RCT18; RC18	Approved	RemeGen Co Ltd		Mainland China	Lupus Erythematosus, Systemic	RemeGen Co Ltd	2021-03-09	Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Nephrosis; Immunoglobulin G4-Related Disease; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic	Details